Brief: Noxopharm Announces New Proprietary Product Candidate Based On MRNA Technology
28/03/2023 02:14
March 28 (Reuters) - Noxopharm Ltd NOX.AX :
* ANNOUNCES DEVELOPMENT OF NEW PROPRIETARY PRODUCT CANDIDATE
BASED
ON MRNA TECHNOLOGY AS PART OF SOFRATM PRECLINICAL PLATFORM
Source text for Eikon: ID:nASX1kkcsD
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsAustralia's Noxopharm hits three-month low on discounted placement
Brief: Noxopharm Receives Commitments For Placement
Brief: Noxopharm Requests Trading Halt Pending Material Capital Raising Announcement
Brief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential